Posted On: 06/22/2013 11:49:01 AM
Post# of 5066
Phenomenal $BMSN D/D Orphan Drug
BMSN**Why a quick FDA Orphan Drug Approval…
Regen BioPharma, a wholly-owned subsidiary of BMSN, has submitted an Investigational New Drug (IND) Application to the FDA nearly two weeks ago for approval of its HemaXellerate I™ stem cell drug to combat Aplastic Anemia. The post below explains why we should be hearing of FDA Approval for Regen BioPharma/BMSN to move forward with their clinical trials within the next 2 to 2 ½ weeks in my opinion:
BMSN**Why a quick FDA Orphan Drug Approval…
Regen BioPharma, a wholly-owned subsidiary of BMSN, has submitted an Investigational New Drug (IND) Application to the FDA nearly two weeks ago for approval of its HemaXellerate I™ stem cell drug to combat Aplastic Anemia. The post below explains why we should be hearing of FDA Approval for Regen BioPharma/BMSN to move forward with their clinical trials within the next 2 to 2 ½ weeks in my opinion:
(0)
(0)
Scroll down for more posts ▼
